NERV - Minerva Neurosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.611M

Cash

35.98M

Avg Qtr Burn

-4.738M

Short % of Float

7.10%

Insider Ownership

3.43%

Institutional Own.

33.17%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roluperidone (5-HT2A antagonist) Details Central nervous system illness, Mental health, Schizophrenia	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.